Oyster Point Pharma, Inc.
If you purchased Oyster Point Pharma, Inc. securities and would like to join the action, please click "Join This Action" below.
OYST ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF OYSTER POINT PHARMA, INC. IS FAIR TO SHAREHOLDERS
November 7, 2022.
New York, New York—Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Oyster Point Pharma, Inc. (NASDAQ: OYST) to Viatris Inc. for $11.00 per share in cash plus a contingent value right for a potential cash payment of up to $2.00 per share upon achievement of specified performance targets is fair to Oyster Point shareholders.
The investigation concerns whether Oyster Point and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Oyster Point shareholders; (2) determine whether Viatris is underpaying for Oyster Point; and (3) disclose all material information necessary for Oyster Point shareholders to adequately assess and value the merger consideration. On behalf of Oyster Point shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.